Baxter International Inc. (BAX) Stock Score, Valuation & Financial Research
Baxter International Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 19/100.
Quick answer for BAX
Baxter International Inc. currently has a Wall Street Score of 19/100. The stored market price is $23.8. Its financial score is 23/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Baxter International Inc. does
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter su
BAX financial snapshot
- Wall Street Score:
- 19/100
- Current price:
- $23.8
- Market capitalization:
- $12.30B
- Revenue:
- $11.47B
- Net income:
- $-1.06B
- Free cash flow:
- $323.0M
- Cash:
- $2.15B
- Total debt:
- $9.67B
- EPS:
- -2.04
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $323.0M, showing positive cash generation.
- The balance sheet shows $2.15B of cash versus $9.67B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BAX increased 0.1 points because overall fundamentals improved.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BAX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.